N/A
Manufactured by Daiichi Sankyo Inc.
9,635 FDA adverse event reports analyzed
Last updated: 2026-04-15
EDOXABAN TOSYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Daiichi Sankyo Inc.. The most commonly reported adverse reactions for EDOXABAN TOSYLATE include ANAEMIA, OFF LABEL USE, RENAL IMPAIRMENT, CARDIAC FAILURE, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for EDOXABAN TOSYLATE.
Out of 6,051 classified reports for EDOXABAN TOSYLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 9,635 FDA FAERS reports that mention EDOXABAN TOSYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ANAEMIA, OFF LABEL USE, RENAL IMPAIRMENT, CARDIAC FAILURE, DYSPNOEA, CEREBRAL INFARCTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Daiichi Sankyo Inc. in connection with EDOXABAN TOSYLATE. Always verify the specific product and NDC with your pharmacist.